Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 1022

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 6
Chunk 1022
---
 consideration, pursuant to the Marketing Services Agreement, in the second
quarter of 2023. The fair value of this stock issuance of $0.1 million was recorded within other income/(expense) in the Company’s
consolidated statements of operations for the fiscal year ended December 31, 2023.

11.
Net loss Per Share

The
Company computes basic loss per share using net loss attributable to stockholders and the weighted-average number of the Company’s
common stock shares outstanding during each period, less shares subject to repurchase under the Backstop Agreement. Diluted earnings
per share include shares issuable upon exercise of outstanding stock options and stock-based awards where the conversion of such instruments
would be dilutive. The Company’s potentially dilutive securities, which include stock options, earnout shares, and warrants to
purchase shares of common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce
the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted
net loss per share attributable to the Company’s stockholders’ is the same.

The
net loss per share for the basic and diluted earnings calculations for the fiscal years ended December 31, 2024 and 2023 is as follows
(in thousands, except share and per share data):

 Schedule of Earnings Per Share, Basic and Diluted

    2024  
    2023 
  
    Numerator: 

    Net loss 
    $(9,480) 
    $(114,466)
  
    Denominator: 

    Weighted-average shares of common stock outstanding, basic and diluted 
     27,502,537  
     26,292,438 
  
    Net loss per common share, basic and diluted 
    $(0.34) 
    $(4.35)

    F-35

As
noted above, the following securities were excluded from the computation of diluted loss per share in the periods presented, as
their effect would be anti-dilutive:

 Schedule of Securities Excluded from Computation of Diluted Loss Per Share 

    2024  
    2023 
  
    Stock options 
     600,000  
     600,000 
  
    Warrants to purchase common stock 
     13,935,001  
     12,602,195 
  
    Anti dilutive securities 
     13,